Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Lexicon Pharmaceuticals, Inc. (LXRX) had Income from Continuous Operations of $-50.34M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$49.80M |
|
$-50.34M |
|
$0.27M |
|
$49.53M |
|
$98.71M |
|
$-48.91M |
|
$-1.43M |
|
$-50.34M |
|
$-50.34M |
|
$-50.34M |
|
|
Income from Continuous Operations |
$-50.34M |
$-50.34M |
|
$-50.34M |
|
$-48.91M |
|
$-46.59M |
|
363.05M |
|
363.05M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$101.89M |
|
$1.86M |
|
$83.09M |
|
$184.99M |
|
$20.87M |
|
$49.41M |
|
$56.58M |
|
$77.45M |
|
$107.54M |
|
$62.99M |
|
$107.54M |
|
365.85M |
|
| Cash Flow Statement Financials | |
$-67.85M |
|
$113.02M |
|
$-48.50M |
|
$66.66M |
|
$63.33M |
|
$-3.33M |
|
$12.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.88 |
|
-- |
|
-- |
|
0.31 |
|
0.50 |
|
99.45% |
|
-98.21% |
|
-98.21% |
|
-93.55% |
|
-101.08% |
|
-101.08% |
|
$-67.85M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
0.98 |
|
20.89 |
|
17.47 |
|
-46.81% |
|
-79.91% |
|
-27.21% |
|
-32.08% |
|
$0.29 |
|
$-0.19 |
|
$-0.19 |
|